These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance. Ball R; Robb M; Anderson SA; Dal Pan G Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601 [TBL] [Abstract][Full Text] [Related]
46. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
47. Reporting of adverse drug events: a key to postmarketing drug safety. Rheinstein PH Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478 [No Abstract] [Full Text] [Related]
48. Adverse drug and device reactions in the oral cavity: surveillance and reporting. Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840 [TBL] [Abstract][Full Text] [Related]
49. How many deaths occur annually from adverse drug reactions in the United States? Chyka PA Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153 [TBL] [Abstract][Full Text] [Related]
51. MEDWATCH: the new FDA medical products reporting program. Kennedy DL Respir Care; 1993 Oct; 38(10):1077-80. PubMed ID: 10145891 [No Abstract] [Full Text] [Related]
52. Strategy for surveillance of adverse drug events. Bright RA Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403 [No Abstract] [Full Text] [Related]
53. MedWatch, the new FDA adverse effects reporting system. Shader RI; Greenblatt DJ J Clin Psychopharmacol; 1993 Oct; 13(5):303-4. PubMed ID: 8227487 [No Abstract] [Full Text] [Related]
54. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases. Shea LL; Hanson A; Guglielmetti TM; Levy K Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388 [No Abstract] [Full Text] [Related]
56. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data. Allan MC J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649 [TBL] [Abstract][Full Text] [Related]
57. Reporting of adverse events to MedWatch. Piazza-Hepp TD; Kennedy DL Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043 [TBL] [Abstract][Full Text] [Related]
58. FDA's MedWatch Program Monitors Drug Safety, But It Depends on Nurses to Report Adverse Events. Miller D ONS Connect; 2015 Sep; 30(3):49. PubMed ID: 26449124 [No Abstract] [Full Text] [Related]
60. Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch. Smith KM; Lawson AP; Tuteja S Am J Health Syst Pharm; 2006 May; 63(10):949-52. PubMed ID: 16675652 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]